HUTCHMED (China) (HCM) vs Supernus Pharmaceuticals (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Supernus Pharmaceuticals (SUPN) has outperformed HUTCHMED (China) (HCM) over the past year, losing 10.4% versus a loss of 10.6%. Over five years, SUPN leads with a +36.0% price change compared with -55.8% for HCM. Supernus Pharmaceuticals is the larger company by market cap ($2.49 billion vs $2.39 billion), about 1.0 times the size.
On valuation, Supernus Pharmaceuticals trades at a lower forward P/E (9.6x vs 53.1x for HUTCHMED (China)). HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | SUPN |
|---|---|---|
| Share price | $13.76 | $42.81 |
| Market cap | $2.39B | $2.49B |
| 1-day change | -3.64% | -0.57% |
| YTD return | +7.13% | -13.38% |
| 1-year return | -10.64% | -10.44% |
| 5-year return | -55.79% | +35.98% |
| P/E ratio (TTM) | 137.60 | — |
| Forward P/E | 53.08 | 9.60 |
| EPS (TTM) | $0.10 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | $718.95M |
| Revenue growth (YoY) | -12.96% | +8.63% |
| Net income (latest FY) | $456.91M | $-38.55M |
| Gross margin | 38.68% | 89.63% |
| Operating margin | -7.14% | -8.66% |
| Net margin | 83.30% | -5.36% |
| 52-week high | $16.33 | $59.68 |
| 52-week low | $9.77 | $40.51 |
| Distance from 52-week high | -15.74% | -28.28% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +59.96% | +44.26% |
| Average volume | 67.70K | 766.52K |
| Shares outstanding | 173.81M | 58.22M |
| Employees | 1,790 | 778 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -5.4 cents for Supernus Pharmaceuticals.
- Supernus Pharmaceuticals grew revenue faster in its latest fiscal year (+8.63% vs -12.96%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About Supernus Pharmaceuticals
SUPN stock →Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
Health Care · Biotechnology: Pharmaceutical Preparations · 778 employees
HCM vs SUPN FAQ
Which is bigger, HUTCHMED (China) or Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) is larger, with a market capitalization of $2.49B compared with $2.39B for HUTCHMED (China) (HCM).
Which stock has performed better over the past year, HCM or SUPN?
SUPN returned -10.44% over the past 12 months, compared with -10.64% for HCM (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and Supernus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.